LogicBio Therapeutics (LOGC) Misses Q4 EPS by 8c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
- S&P 500, Nasdaq end sharply lower as revived AI doubts ignite tech selloff
- Meta’s new Class C stock to keep Zuckerberg in California, fund AI spending spree
- Oil hits five-month high as Houthi attacks stoke supply fears
- Meta beats Q3 estimates, approves new nonvoting share class as AI spending surges
- Tesla stock up as automotive gross margin improves, free cash flow turns positive
Tweet
Share
E-mailGet Alerts LOGC Hot Sheet
Price: $7.06 --0%
EPS Growth %: +42.9%
Financial Fact:
Total operating expenses: 292.2K
Today's EPS Names:
RCBC, SSL, PFBC, More
EPS Growth %: +42.9%
Financial Fact:
Total operating expenses: 292.2K
Today's EPS Names:
RCBC, SSL, PFBC, More
Join SI Premium – FREE
LogicBio Therapeutics (NASDAQ: LOGC) reported Q4 EPS of ($0.08).
For earnings history and earnings-related data on LogicBio Therapeutics (LOGC) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Raymond James Downgrades Old Republic International (ORI) to Outperform
- Commercial National Financial (CNAF) Reports Q3 EPS of $0.24
- KeyBanc Starts Astronics (ATRO) at Sector Weight
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
